The global Mycobacterium Tuberculosis Treatment market size is predicted to grow from US$ 2350 million in 2025 to US$ 3202 million in 2031; it is expected to grow at a CAGR of 5.3% from 2025 to 2031.
The treatment of Mycobacterium tuberculosis (TB) infection involves a combination of antibiotics over an extended period. The goal of treatment is to eliminate the bacteria, prevent the development of drug resistance, and reduce the risk of transmission to others. Tuberculosis can be treated effectively with the appropriate medications, but adherence to the prescribed regimen is crucial to ensure successful outcomes. Treatment plans may vary based on factors such as the type of TB (latent or active), drug susceptibility, and the patient"s overall health.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
The 鈥淢ycobacterium Tuberculosis Treatment Industry Forecast鈥� looks at past sales and reviews total world Mycobacterium Tuberculosis Treatment sales in 2024, providing a comprehensive analysis by region and market sector of projected Mycobacterium Tuberculosis Treatment sales for 2025 through 2031. With Mycobacterium Tuberculosis Treatment sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Mycobacterium Tuberculosis Treatment industry.
This Insight Report provides a comprehensive analysis of the global Mycobacterium Tuberculosis Treatment landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Mycobacterium Tuberculosis Treatment portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Mycobacterium Tuberculosis Treatment market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Mycobacterium Tuberculosis Treatment and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Mycobacterium Tuberculosis Treatment.
This report presents a comprehensive overview, market shares, and growth opportunities of Mycobacterium Tuberculosis Treatment market by product type, application, key players and key regions and countries.
Segmentation by Type:
Oral
Intravenous
Intramuscular
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
AstraZeneca
Johnson & Johnson Private Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Allergan
Merck & Co., Inc.
Pfizer Inc.
GlaxoSmithKline plc
Hikma Pharmaceuticals PLC
Cipla Inc.
Endo International plc
Otsuka Pharmaceutical Co., Ltd.
STI Pharma, LLC
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Mycobacterium Tuberculosis Treatment 麻豆原创 Size (2020-2031)
2.1.2 Mycobacterium Tuberculosis Treatment 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Mycobacterium Tuberculosis Treatment by Country/Region (2020, 2024 & 2031)
2.2 Mycobacterium Tuberculosis Treatment Segment by Type
2.2.1 Oral
2.2.2 Intravenous
2.2.3 Intramuscular
2.3 Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Type
2.3.1 Mycobacterium Tuberculosis Treatment 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Mycobacterium Tuberculosis Treatment 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Mycobacterium Tuberculosis Treatment Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Application
2.5.1 Mycobacterium Tuberculosis Treatment 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Mycobacterium Tuberculosis Treatment 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Player
3.1 Mycobacterium Tuberculosis Treatment 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Mycobacterium Tuberculosis Treatment Revenue by Player (2020-2025)
3.1.2 Global Mycobacterium Tuberculosis Treatment Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Mycobacterium Tuberculosis Treatment Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Mycobacterium Tuberculosis Treatment by Region
4.1 Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Region (2020-2025)
4.2 Global Mycobacterium Tuberculosis Treatment Annual Revenue by Country/Region (2020-2025)
4.3 Americas Mycobacterium Tuberculosis Treatment 麻豆原创 Size Growth (2020-2025)
4.4 APAC Mycobacterium Tuberculosis Treatment 麻豆原创 Size Growth (2020-2025)
4.5 Europe Mycobacterium Tuberculosis Treatment 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Mycobacterium Tuberculosis Treatment 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Country (2020-2025)
5.2 Americas Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Type (2020-2025)
5.3 Americas Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Region (2020-2025)
6.2 APAC Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Type (2020-2025)
6.3 APAC Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Country (2020-2025)
7.2 Europe Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Type (2020-2025)
7.3 Europe Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Mycobacterium Tuberculosis Treatment by Region (2020-2025)
8.2 Middle East & Africa Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Mycobacterium Tuberculosis Treatment 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Mycobacterium Tuberculosis Treatment 麻豆原创 Forecast
10.1 Global Mycobacterium Tuberculosis Treatment Forecast by Region (2026-2031)
10.1.1 Global Mycobacterium Tuberculosis Treatment Forecast by Region (2026-2031)
10.1.2 Americas Mycobacterium Tuberculosis Treatment Forecast
10.1.3 APAC Mycobacterium Tuberculosis Treatment Forecast
10.1.4 Europe Mycobacterium Tuberculosis Treatment Forecast
10.1.5 Middle East & Africa Mycobacterium Tuberculosis Treatment Forecast
10.2 Americas Mycobacterium Tuberculosis Treatment Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.2.2 Canada 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.2.3 Mexico 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.2.4 Brazil 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.3 APAC Mycobacterium Tuberculosis Treatment Forecast by Region (2026-2031)
10.3.1 China Mycobacterium Tuberculosis Treatment 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.3.3 Korea 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.3.4 Southeast Asia 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.3.5 India 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.3.6 Australia 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.4 Europe Mycobacterium Tuberculosis Treatment Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.4.2 France 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.4.3 UK 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.4.4 Italy 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.4.5 Russia 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.5 Middle East & Africa Mycobacterium Tuberculosis Treatment Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.5.2 South Africa 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.5.3 Israel 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.5.4 Turkey 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
10.6 Global Mycobacterium Tuberculosis Treatment Forecast by Type (2026-2031)
10.7 Global Mycobacterium Tuberculosis Treatment Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Mycobacterium Tuberculosis Treatment Forecast
11 Key Players Analysis
11.1 AstraZeneca
11.1.1 AstraZeneca Company Information
11.1.2 AstraZeneca Mycobacterium Tuberculosis Treatment Product Offered
11.1.3 AstraZeneca Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 AstraZeneca Main Business Overview
11.1.5 AstraZeneca Latest Developments
11.2 Johnson & Johnson Private Limited
11.2.1 Johnson & Johnson Private Limited Company Information
11.2.2 Johnson & Johnson Private Limited Mycobacterium Tuberculosis Treatment Product Offered
11.2.3 Johnson & Johnson Private Limited Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Johnson & Johnson Private Limited Main Business Overview
11.2.5 Johnson & Johnson Private Limited Latest Developments
11.3 Eli Lilly and Company
11.3.1 Eli Lilly and Company Company Information
11.3.2 Eli Lilly and Company Mycobacterium Tuberculosis Treatment Product Offered
11.3.3 Eli Lilly and Company Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Eli Lilly and Company Main Business Overview
11.3.5 Eli Lilly and Company Latest Developments
11.4 F. Hoffmann-La Roche Ltd.
11.4.1 F. Hoffmann-La Roche Ltd. Company Information
11.4.2 F. Hoffmann-La Roche Ltd. Mycobacterium Tuberculosis Treatment Product Offered
11.4.3 F. Hoffmann-La Roche Ltd. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 F. Hoffmann-La Roche Ltd. Main Business Overview
11.4.5 F. Hoffmann-La Roche Ltd. Latest Developments
11.5 Mylan N.V.
11.5.1 Mylan N.V. Company Information
11.5.2 Mylan N.V. Mycobacterium Tuberculosis Treatment Product Offered
11.5.3 Mylan N.V. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Mylan N.V. Main Business Overview
11.5.5 Mylan N.V. Latest Developments
11.6 Teva Pharmaceutical Industries Ltd.
11.6.1 Teva Pharmaceutical Industries Ltd. Company Information
11.6.2 Teva Pharmaceutical Industries Ltd. Mycobacterium Tuberculosis Treatment Product Offered
11.6.3 Teva Pharmaceutical Industries Ltd. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 Teva Pharmaceutical Industries Ltd. Main Business Overview
11.6.5 Teva Pharmaceutical Industries Ltd. Latest Developments
11.7 Sanofi
11.7.1 Sanofi Company Information
11.7.2 Sanofi Mycobacterium Tuberculosis Treatment Product Offered
11.7.3 Sanofi Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Sanofi Main Business Overview
11.7.5 Sanofi Latest Developments
11.8 Novartis AG
11.8.1 Novartis AG Company Information
11.8.2 Novartis AG Mycobacterium Tuberculosis Treatment Product Offered
11.8.3 Novartis AG Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Novartis AG Main Business Overview
11.8.5 Novartis AG Latest Developments
11.9 Sun Pharmaceutical Industries Ltd.
11.9.1 Sun Pharmaceutical Industries Ltd. Company Information
11.9.2 Sun Pharmaceutical Industries Ltd. Mycobacterium Tuberculosis Treatment Product Offered
11.9.3 Sun Pharmaceutical Industries Ltd. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Sun Pharmaceutical Industries Ltd. Main Business Overview
11.9.5 Sun Pharmaceutical Industries Ltd. Latest Developments
11.10 Aurobindo Pharma
11.10.1 Aurobindo Pharma Company Information
11.10.2 Aurobindo Pharma Mycobacterium Tuberculosis Treatment Product Offered
11.10.3 Aurobindo Pharma Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Aurobindo Pharma Main Business Overview
11.10.5 Aurobindo Pharma Latest Developments
11.11 Lupin
11.11.1 Lupin Company Information
11.11.2 Lupin Mycobacterium Tuberculosis Treatment Product Offered
11.11.3 Lupin Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 Lupin Main Business Overview
11.11.5 Lupin Latest Developments
11.12 Allergan
11.12.1 Allergan Company Information
11.12.2 Allergan Mycobacterium Tuberculosis Treatment Product Offered
11.12.3 Allergan Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Allergan Main Business Overview
11.12.5 Allergan Latest Developments
11.13 Merck & Co., Inc.
11.13.1 Merck & Co., Inc. Company Information
11.13.2 Merck & Co., Inc. Mycobacterium Tuberculosis Treatment Product Offered
11.13.3 Merck & Co., Inc. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Merck & Co., Inc. Main Business Overview
11.13.5 Merck & Co., Inc. Latest Developments
11.14 Pfizer Inc.
11.14.1 Pfizer Inc. Company Information
11.14.2 Pfizer Inc. Mycobacterium Tuberculosis Treatment Product Offered
11.14.3 Pfizer Inc. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Pfizer Inc. Main Business Overview
11.14.5 Pfizer Inc. Latest Developments
11.15 GlaxoSmithKline plc
11.15.1 GlaxoSmithKline plc Company Information
11.15.2 GlaxoSmithKline plc Mycobacterium Tuberculosis Treatment Product Offered
11.15.3 GlaxoSmithKline plc Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 GlaxoSmithKline plc Main Business Overview
11.15.5 GlaxoSmithKline plc Latest Developments
11.16 Hikma Pharmaceuticals PLC
11.16.1 Hikma Pharmaceuticals PLC Company Information
11.16.2 Hikma Pharmaceuticals PLC Mycobacterium Tuberculosis Treatment Product Offered
11.16.3 Hikma Pharmaceuticals PLC Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Hikma Pharmaceuticals PLC Main Business Overview
11.16.5 Hikma Pharmaceuticals PLC Latest Developments
11.17 Cipla Inc.
11.17.1 Cipla Inc. Company Information
11.17.2 Cipla Inc. Mycobacterium Tuberculosis Treatment Product Offered
11.17.3 Cipla Inc. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 Cipla Inc. Main Business Overview
11.17.5 Cipla Inc. Latest Developments
11.18 Endo International plc
11.18.1 Endo International plc Company Information
11.18.2 Endo International plc Mycobacterium Tuberculosis Treatment Product Offered
11.18.3 Endo International plc Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 Endo International plc Main Business Overview
11.18.5 Endo International plc Latest Developments
11.19 Otsuka Pharmaceutical Co., Ltd.
11.19.1 Otsuka Pharmaceutical Co., Ltd. Company Information
11.19.2 Otsuka Pharmaceutical Co., Ltd. Mycobacterium Tuberculosis Treatment Product Offered
11.19.3 Otsuka Pharmaceutical Co., Ltd. Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 Otsuka Pharmaceutical Co., Ltd. Main Business Overview
11.19.5 Otsuka Pharmaceutical Co., Ltd. Latest Developments
11.20 STI Pharma, LLC
11.20.1 STI Pharma, LLC Company Information
11.20.2 STI Pharma, LLC Mycobacterium Tuberculosis Treatment Product Offered
11.20.3 STI Pharma, LLC Mycobacterium Tuberculosis Treatment Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 STI Pharma, LLC Main Business Overview
11.20.5 STI Pharma, LLC Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
